22:36 , Mar 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting NR4A1, NR4A2 and N4RA3 in CAR Ts to enhance efficacy in solid tumors

DISEASE CATEGORY: Cancer INDICATION: Melanoma; colorectal cancer Mouse studies suggest inhibiting NR4A1, NR4A2 and NR4A3 in CAR T cells could enhance the cells' efficacy in melanoma, colorectal cancer and other solid tumor types. In CD8+...
13:02 , Feb 28, 2019 |  BC Extra  |  Preclinical News

Removing genes from CAR Ts to improve efficacy, safety

Two studies have identified genes that could be knocked out from CAR T cells to improve efficacy or safety. While CAR T cells are effective against B cell malignancies, their efficacy in solid tumors has...
20:31 , Jan 25, 2018 |  BC Innovations  |  Translation in Brief

Melanoma vs. melanoma

A Northwestern University team has discovered that some non-metastatic melanoma cells carry a signal, pigment epithelium derived factor (PEDF), that can induce immune-mediated killing of metastatic cells, pointing toward a new immunotherapeutic strategy for the...
08:00 , Jan 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear receptor subfamily 4 group A member 1 (NR4A1; NURR77); tyrosine hydroxylase (TYH)

Autoimmune disease INDICATION: Multiple sclerosis (MS) In vitro and mouse studies suggest promoting NR4A1 expression or inhibiting TYH could help treat MS. In monocytes from MS patients, TYH levels were higher than in monocytes from...
08:00 , Dec 3, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear receptor subfamily 4 group A member 1 (NR4A1; NURR77)

Cancer INDICATION: Lung cancer Mouse studies suggest adoptive transfer of NR4A1-expressing monocytes could help prevent metastasis of cancer to the lungs. In mice, the number of a subset of NR4A1-expressing monocytes (patrolling monocytes) was higher...
08:00 , Mar 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear receptor subfamily 4 group A member 1 (NR4A1, NGFI-B, NURR77)

Various INDICATION: Dermatology; kidney fibrosis; liver fibrosis; pulmonary fibrosis Mouse studies suggest NR4A1 agonists could help treat multiple types of fibrosis. In a mouse model of transforming growth factor (TGF)-β-driven skin fibrosis, NR4A1 knockout increased...
07:00 , Oct 30, 2008 |  BC Innovations  |  Cover Story

BCL-2 double take

Researchers at the Burnham Institute for Medical Research and the Dana-Farber Cancer Institute have independently identified peptides that modulate mitochondrial apoptosis and may have promise in cancer. The therapeutic strategies are, however, quite different: in...
01:05 , May 23, 2007 |  BC Extra  |  Clinical News

Researchers link NR4A1, NR4A3 to AML

Researchers from Baylor College of Medicine and colleagues reported in Nature Medicine a previously unknown function of the highly homologous orphan nuclear receptors NR4A1 (Nur77) and NR4A3 (Nor-1). They described the receptors' role as suppressors...